Bioventus Inc. (NASDAQ:BVS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $16.80.

BVS has been the topic of several recent analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, August 17th. Barrington Research set a $18.00 target price on shares of Bioventus in a research note on Thursday, August 6th. Canaccord Genuity Group upped their price target on shares of Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Weiss Ratings raised shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th.

Bioventus Price Performance

NASDAQ BVS opened at $13.63 on Thursday. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. Bioventus has a 12-month low of $6.26 and a 12-month high of $15.89. The company has a market capitalization of $1.15 billion, a PE ratio of 17.70, a price-to-earnings-growth ratio of 1.76 and a beta of 0.65. The firm’s 50 day moving average is $13.14 and its 200-day moving average is $10.66.

Bioventus (NASDAQ:BVS) last released its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The business had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts anticipate that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP lifted its holdings in Bioventus by 0.4% during the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after purchasing an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after buying an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after buying an additional 1,887 shares in the last quarter. Deutsche Bank AG increased its position in Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares during the period. Finally, California State Teachers Retirement System increased its position in Bioventus by 147.4% during the 2nd quarter. California State Teachers Retirement System now owns 6,174 shares of the company’s stock worth $58,000 after buying an additional 3,678 shares during the period. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.